• KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC

    A pooled analysis from the ARCAD CRC Database found that patients with KRAS mutations and liver metastases had significantly worse prognosis in third-line placebo-controlled trials. This analysis helps identify patients who may need more aggressive treatment strategies earlier in their disease course. (Clinical Colorectal Cancer)

  • Sotorasib Plus Panitumumab Compared to Standard Chemotherapy in KRAS G12C Metastatic CRC

    An indirect comparison evaluated sotorasib plus panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer with KRAS G12C mutations. This research addresses treatment options for patients with this specific mutation who have exhausted standard chemotherapy. (Clinical Colorectal Cancer)

  • Treatment Delays Linked to Higher Metastasis Risk in Nonmetastatic CRC

    A cohort study of US patients aged 40 and older found that longer time-to-treatment initiation was associated with increased 3-year metastasis risk in patients with newly diagnosed nonmetastatic colorectal cancer undergoing curative-intent surgery. The findings underscore the importance of timely care coordination after diagnosis. (JAMA Network Open)

  • Wing-Attachment Hood May Improve Adenoma Detection During Colonoscopy

    A randomized trial of 800 patients compared Endo-Wing-assisted colonoscopy versus transparent hood-assisted colonoscopy, both with linked color imaging and computer-aided detection, to evaluate adenoma detection rates and determine whether hood design affects the identification of precancerous polyps during screening. (Endoscopy International Open)

  • Meta-Analysis Confirms Targeted Therapy Benefits for Colorectal Cancer Liver Metastases

    A systematic review and meta-analysis evaluated targeted therapy in colorectal cancer liver metastases, examining overall survival, progression-free survival, objective response rate, and conversion to resection. The analysis provides comprehensive evidence on the role of targeted agents in managing liver-limited disease. (Translational Cancer Research)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Research continues to refine treatment strategies and improve early detection — progress that matters for every patient navigating this journey.